Potential Zika Vaccine to Start Human Trials

The U.S. Food and Drug Administration (FDA) gave a green light Monday to the first human trial of a potential Zika vaccine.

Inovio Pharmaceuticals and GeneOne Life Science are at the helm of the study and have already conducted promising animal trials. They say that they will begin phase one with 40 healthy adults in the next coming weeks. Dubbed GLS-5700, the vaccine is based on synthetic fragments of virus DNA that stimulate antibodies, according to the Guardian.